Immunic, Inc. Aktie News

Immunic Inc (NASDAQ:IMUX) said it will present additional analyses from its Phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the ACTRIMS Forum 2026, which is being held from February 5 to 7 in San Diego. Vidofludimus calcium is described by Immunic as a nuclear receptor-related 1 (Nurr1) activator and selective dihydroorotate dehy...

– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity – – CALLIPER Subset Data Demonstrate Reductions in EBV-Specific T-Cell Receptor Sequences, Underlining Broad-Spectrum Antiviral Effects of Vidofludimus Calcium – NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pio...

Immunic AG / US4525EP1011

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's major milestones in 2025 and key expectations for 2026. He highlighted the significance of the phase 2 CALLIPER study, which demonstrated a 31% reduction in confirmed disability worsening in patients with progressive multiple sclerosis (MS), and a 34% reduction in those without baseline gadolinium lesions.

Immunic Inc (NASDAQ:IMUX) said on Wednesday it is entering a pivotal phase for its lead multiple sclerosis drug as the biotech company prepares for key clinical readouts that could shape its longer-term growth strategy. The Nasdaq-listed company said it has completed patient enrollment in two late-stage Phase 3 trials of vidofludimus calcium, an oral therapy being tested in relapsing multiple s...

– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 – – Phase 2 CALLIPER Data Showed Vidofludimus Calcium Reduced 24-Week Confirmed Disability Worsening and Increased 24-Week Confirmed Disability Improvement Across Progressive Multiple Sclerosis and Its Subtypes, Reinforcing the Drug's Direct Neurop...

Immunic Inc (NASDAQ:IMUX) earlier this week highlighted the long-term clinical potential of its lead compound vidofludimus calcium in treating multiple sclerosis (MS). Speaking to Proactive, Chief Scientific Officer Dr.

NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healt...